Company news

Arrowhead Pharmaceuticals, Inc. news in 2026

Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

November 4, 2026

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

November 3, 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

November 2, 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

October 27, 2026

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

October 14, 2026

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

October 7, 2026

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 29, 2026

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

September 15, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

September 3, 2026

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

August 30, 2026

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

August 24, 2026

Arrowhead Pharmaceuticals - People Living with Familial Chylomicronaemia Syndrome in Germany Have Access to REDEMPLO as a New Treatment Option to Reduce Triglycerides

August 18, 2026

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

August 17, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

August 4, 2026

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

August 4, 2026

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 27, 2026

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

July 22, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

July 21, 2026

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

June 23, 2026

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

June 22, 2026

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

June 18, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

June 2, 2026

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

May 27, 2026

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

May 26, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

May 7, 2026

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 4, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

May 4, 2026

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

May 1, 2026

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe

April 27, 2026

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

April 24, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

April 20, 2026

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

March 30, 2026

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

March 27, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

February 24, 2026

ARWR: Strong Start for REDEMPLO Commercialization…

February 11, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

February 5, 2026

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

February 4, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

January 27, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

January 20, 2026

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

January 7, 2026

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

January 7, 2026

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

January 6, 2026

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

January 6, 2026

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

January 4, 2026

Calls in 2026

Decks in 2026